Nasal Cavity Cooling for Migraine Trial, Utilizing BeneChill’s Proprietary Cooling System, Wins NHS’s 12th Bright Ideas in Health Awards
COOLHEAD Pilot Trial Receives First Prize in the Innovative
Technology or Device Category
San Diego, CA – June 2, 2015 – BeneChill, Inc. (“BeneChill”, the “Company”) is
pleased to announce the recognition of the results of the ‘COOLHEAD’ clinical trial
by virtue of its award as the 2015 winner in the Innovation Technology or Device
Category for NHS’s annual Bright Ideas in Health Awards. The award recognizes
leaders in research and innovation within the NHS in the United Kingdom.
The concept of utilizing nasal cavity cooling for the treatment of acute migraine,
as provided by the RhinoChill® System, was developed by Fred Colen, MSEE, CEO of
BeneChill. To substantiate the concept, Dr. Jitka Vanderpol from Cumbria
Partnership NHS Foundation Trust and the COOLHEAD team developed and
conducted the breakthrough COOLHEAD pilot trial at the Penrith Community
Hospital, part of the Cumbria Partnership NHS Foundation Trust and published the
Out of four finalists, Cumbria Partnership was recognized as the frontrunner for
their successful results from the COOLHEAD pilot trial, a study designed to assess
the benefits of nasal cavity cooling for the treatment of migraine headaches. The
winning team was comprised of: Dr. Jitka Vanderpol, Barbara Bishop, Gillian
Webster, Dr. Dave Dagnan, Sandra Glencorse, Dale Healy, Mark Glencorse, Fred
Colen and Dr. Manjit Matharu.
The full results from the COOLHEAD trial were published in January, 2015 in the
Journal of Headache and Pain.
“I am honored to have been selected as the winner given the many talented peers
who applied for the Bright Ideas in Health Awards. Results from the COOLHEAD
study illustrate a promising and revolutionary non- pharmacological approach for
treating the millions of individuals who suffer from migraine headaches. The
COOLHEAD 2 trial will begin recruiting in July of this year to further support
evidence of benefit for this exciting new treatment for migraine sufferers around
the world” stated Dr. Vanderpol.
“Winning the 12th Bright Ideas in Health Awards is a wonderful validation of our
technology and the benefit it can provide for millions of migraine patients needing
better treatment options,” remarked Fred Colen, CEO of BeneChill. “The added
recognition we are receiving from the healthcare industry and the medical
community as a result of the award allows us to showcase BeneChill’s mission of
offering a simple, fast and effective solution for treating migraine headaches. Our
goal is to expand upon the positive results from the COOLHEAD study and further
validate the benefits of nasal cavity cooling for the treatment of migraine
About BeneChill, Inc.
BeneChill, Inc. is a medical device company established in 2003 to develop, manufacture,
and sell novel rapid cooling products to improve clinical outcomes. BeneChill’s lead
product, the RhinoChill® IntraNasal Cooling System (also referred to as the RhinoChill®
System, “RhinoChill®”, or the “System”), is designed to deliver targeted, effective and
therapeutically beneficial cooling to the nasal cavity and the brain (and to the body via the
cooled brain, if so desired). Utilizing a lightweight, portable system design and unique
intra-nasal, catheter-based delivery of a quickly evaporating coolant, BeneChill offers a
unique opportunity for medical practitioners to protect the brain. BeneChill’s cooling
technology is also suitable for applications on conscious patients where a local, short
duration cooling of the nasal cavity is of therapeutic benefit, such as for the treatment of
acute migraine. BeneChill’s treatment can also be used during Cardiac Arrest, potentially
during Traumatic Brain Injury and may be applicable for other surgical procedures.
BeneChill is headquartered in San Diego, CA with European locations near Zürich,
Switzerland and Düsseldorf, Germany. BeneChill products, while CE marked in Europe for
cooling application, are not FDA approved and not available in the US. For further
information please visit www.benechill.com.
Certain matters discussed in this release may constitute forward looking statements for the
purposes of the Federal Securities Laws, and as such, may involve known and unknown risk.
Uncertainties and other factors may cause actual results, performance or activities of
BeneChill, Inc. to be materially different from future results of performance or
achievements expressed or implied by such forward looking statements. Additional
information concerning factors that could cause actual results to be materially different
than those in forward looking statements can be found in BeneChill, Inc.’s filings with the
Securities and Exchange Commission (SEC). All forward-looking statements are expressly
qualified in their entirety by these cautionary statements.
BeneChill, Inc. Contact:
Fred Colen, Chief Executive Officer
Investor Relations Contact:
Jennifer K. Zimmons, Ph.D., Investor Relations
Source: BeneChill NHS Award-June-2015